Galapagos (NASDAQ:GLPG) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a research report sent to investors on Sunday morning.

GLPG has been the subject of a number of other reports. Royal Bank Of Canada raised their target price on shares of Galapagos from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Galapagos in a research note on Wednesday, October 8th. Sanford C. Bernstein began coverage on Galapagos in a report on Wednesday, November 26th. They set a “hold” rating on the stock. Leerink Partners set a $40.00 target price on shares of Galapagos and gave the stock an “outperform” rating in a report on Tuesday, October 21st. Finally, Leerink Partnrs raised shares of Galapagos from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $31.33.

Galapagos Trading Down 2.7%

Shares of Galapagos stock opened at $31.69 on Friday. Galapagos has a 52 week low of $22.36 and a 52 week high of $37.78. The company’s 50-day moving average price is $32.03 and its two-hundred day moving average price is $31.46.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new stake in shares of Galapagos during the 2nd quarter valued at $28,000. GAMMA Investing LLC raised its holdings in shares of Galapagos by 79.4% during the third quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 652 shares in the last quarter. Quadrant Capital Group LLC acquired a new stake in Galapagos during the third quarter valued at $134,000. Squarepoint Ops LLC acquired a new stake in Galapagos during the third quarter valued at $211,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Galapagos in the third quarter valued at about $212,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.